...
首页> 外文期刊>Journal of Immune Based Therapies Vaccines >Ex vivo development, expansion and in vivo analysis of a novel lineage of dendritic cells from hematopoietic stem cells
【24h】

Ex vivo development, expansion and in vivo analysis of a novel lineage of dendritic cells from hematopoietic stem cells

机译:造血干细胞的新型树突状细胞的体外发育,扩增和体内分析

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Dendritic cells (DCs) play a key role in innate and adaptive immunity but the access to sufficient amount of DCs for basic and translational research has been limited. We established a novel ex vivo system to develop and expand DCs from hematopoietic stem/progenitor cells (HPCs). Both human and mouse HPCs were expanded first in feeder culture supplemented with c-Kit ligand (KL, stem cell factor, steel factor or CD117 ligand), Flt3 ligand (fms-like tyrosine kinase 3, Flt3L, FL), thrombopoietin (TPO), IL-3, IL-6, and basic fibroblast growth factor (bFGF), and then in a second feeder culture ectopically expressing all above growth factors plus GM-CSF and IL-15. In the dual culture system, CD34+ HPCs differentiated toward DC progenitors (DCPs), which expanded more than five orders of magnitude. The DCPs showed myeloid DC surface phenotype with up-regulation of transcription factors PU.1 and Id2, and DC-related factors homeostatic chemokine ligand 17 (CCL17) and beta-chemokine receptor 6 (CCR6). Multiplex ELISA array and cDNA microarray analyses revealed that the DCPs shared some features of IL-4 and IL-15 DCs but displayed a pronounced proinflammatory phenotype. DCP-derived DCs showed antigen-uptake and immune activation functions analogous to that of the peripheral blood-derived DCs. Furthermore, bone marrow HPC-derived DCP vaccines of tumor-bearing mice suppressed tumor growth in vivo. This novel approach of generating DCP-DCs, which are different from known IL-4 and IL-15 DCs, overcomes both quantitative and qualitative limitations in obtaining functional autologous DCs from a small number of HPCs with great translational potential.
机译:树突状细胞(DC)在先天和适应性免疫中起着关键作用,但是用于基础和转化研究的足够量DC的获取受到了限制。我们建立了一个新型的离体系统,以从造血干/祖细胞(HPC)开发和扩展DC。人类和小鼠的HPC首先在饲养细胞培养中扩增,并补充c-Kit配体(KL,干细胞因子,钢因子或CD117配体),Flt3配体(fms样酪氨酸激酶3,Flt3L,FL),血小板生成素(TPO) ,IL-3,IL-6和碱性成纤维细胞生长因子(bFGF),然后在第二饲养层培养中异位表达上述所有生长因子以及GM-CSF和IL-15。在双重培养系统中,CD34 + HPC向DC祖细胞(DCP)分化,DC祖细胞扩展了五个以上的数量级。 DCPs显示出具有转录因子PU.1和Id2以及DC相关因子稳态趋化因子配体17(CCL17)和β趋化因子受体6(CCR6)上调的髓样DC表面表型。多重ELISA阵列和cDNA微阵列分析显示,DCP具有IL-4和IL-15 DC的某些特征,但显示出明显的促炎表型。 DCP衍生的DC表现出与外周血DC相似的抗原摄取和免疫激活功能。此外,荷瘤小鼠的骨髓HPC衍生的DCP疫苗抑制了体内肿瘤的生长。这种不同于已知的IL-4和IL-15 DC的生成DCP-DC的新颖方法,克服了从少量具有很大翻译潜力的HPC获得功能性自体DC的定量和定性限制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号